Chinese Bioscience Association presents

BIG DATA, AI, AND CUTTING-EDGE CHEMISTRY IN PRECISION MEDICINE AND LONGEVITY

25th Annual Conference

Sept. 30, 2023
8:00AM – 7:00PM PST

Crowne Plaza Hotel
1221 Chess Drive
Foster City, CA

CBA Chinese Bioscience Association
www.cbasf.org

CBA MISSION

To Promote Networking

Serve the life science professionals' interest in the Bay Area and facilitate networking between professionals locally and globally

To Promote Awareness

Enhance public awareness of the progress and development of the life science industry

To Update and Educate

Facilitate a better understanding of key trends in life science as well as encouraging scientific innovations to address unmet medical needs

To Foster Collaboration

Establish active collaborations with other organizations in areas of mutual interests

CBA MEMBERSHIP & BENEFITS

- Networking opportunities for success
- Connect with other professionals and share technical interests
- Keep skills and knowledge current and relevant
- Create new partnerships
- Free or discounted admission to seminars and workshops
- Free admission to Annual Summer Picnic
- Discounted admission to Annual Conference
- Access to career resources through job posting portal
- Eligibility to vote or become a board member

Editor-in-Chief: Xinye Qian, Jessie Zhang
Cover Design: Katherine Cao
Content Editing and Quality: Charlie Ao, Xinguo Jiang, Xinye Qian, Jessie Zhang

Published for Annual Conference, Education and Communication

www.cbasf.org Email: info@cbasf.org

Chinese Bioscience Association



Table of Contents



State of the Association

It is an honor and a great source of enthusiasm to serve as the President of the Chinese Bioscience Association (CBA) for the year 2023. Since its establishment in 1997, CBA has grown significantly, attracting more than a thousand members and establishing a vibrant professional community where individuals with backgrounds in bioscience and related fields can come together to exchange ideas. Over the past two decades, the field of biological science has witnessed transformative advancements, largely due to the emergence of new technologies such as high-speed sequencing, multi-omics, and machine learning. These developments have significantly contributed to our understanding of biology and expedited the discovery of new targets for the development of more effective treatments for both acute and chronic diseases, including age-related illnesses.

The rise of artificial intelligence (AI), exemplified by ChatGPT, has already had a profound impact on various aspects of our lives. Understanding how similar technologies may influence biomedical research and the biotech industry has become a pressing topic for professionals in our field.

The 25th annual conference of the CBA will focus on the theme of big data and AI in precision medicine, with a particular emphasis on aging. We are delighted to announce that our lineup of speakers for the conference includes esteemed experts such as Dr. Michael Snyder, Chair of Genetics and Director of Genomics and Personalized Medicine at Stanford University, who is globally recognized as a leader in the field. Additionally, we will be joined by Dr. Carolyn Bertozzi, the 2022 Nobel Prize laureate for her groundbreaking work on bioorthogonal chemistry and a renowned expert in glycobiology from Stanford University. Another distinguished speaker will be Dr. Juan Carlos Izpisua Belmonte, Director of the San Diego Institute of Science of Altos Labs, who is a leading scientific innovator in cellular reprogramming and aging. Furthermore, the conference will feature sessions dedicated to entrepreneurship and investment.

We extend a warm invitation to you to attend our annual conference. It promises to be an excellent opportunity to gain insights into the latest advances from esteemed experts and network with leaders in academia and industry.

CBA Chinese Bioscience Association



Lastly, I would like to express my gratitude to all our sponsors, volunteers, and members for their unwavering support. It is through your contributions and participation that CBA's annual conference has been made possible.

Welcome to CBA's 25th annual conference, and we hope you enjoy the day!

Sincerely yours,

Xinguo Jiang MD, PhD
CBA President (2023)



Welcome Remarks

Welcome to the 2023 Chinese Bioscience Association (CBA) conference. It is our distinct pleasure to extend a warm welcome to the 25th Annual Chinese Bioscience Association Conference. As this year's conference co-chairs, We are truly honored to lead this assembly of brilliant minds and visionaries.

Our voyage through the past 26 years has been truly extraordinary. The Chinese Bioscience Association has grown and thrived, evolving into a dynamic force in the realm of bioscience. This annual conference has remained a steadfast beacon of knowledge exchange, collaboration, and innovation.

Today, we not only commemorate the longevity of our organization but also celebrate our relentless pursuit of excellence in the field of bioscience. Our theme for this year's conference is "Precision Medicine and Longevity Enabled by Big Data and Novel Chemistry" This theme underscores our unwavering commitment to pushing the frontiers of research and harnessing the potential of cutting-edge technologies to advance healthcare and enhance the quality of life.

Our morning session will feature two exceptional sessions. The first, "Dreams to Healthy Longevity,", a keynote presented by Dr. Juan Carlos Izpisua Belmonte, Founding Scientist and Director of Science at Altos Labs. Here, we will immerse ourselves in the captivating realm of cellular health rejuvenation. We will then hear from Dr. Oliver Hahn, Principal Investigator from Calico, and Dr. Marco Quarta, Co-founder and CEO of Rubedo Life Science on targeting brain aging hotspots and treating aging diseases through understanding heterogeneity in cellular senescence. The knowledge shared today will undoubtedly mold the future landscape of healthcare.

After a short break, we will enter the "Groundbreaking Chemistry in Medicine" session by Dr. Carolyn Bertozzi, the 2022 Nobel Prize in Chemistry from Stanford University. She will tell us her journey from benchside to bedside entailing bioorthogonal chemistry. The last speaker in the morning session will be Dr. Stanley Qi, Professor at Stanford Bioengineering and co-founder of Epic Bio, using CRISPR chemistry to modify the epigenome for therapeutics.

In the afternoon, we are delighted to present the Elevator Pitch session, showcasing the winners of the CBA Entrepreneur Pitch event. You will be introduced to innovative diagnostics, treatments, and therapies that hold the potential to revolutionize healthcare.

After the Elevator Pitch session, our afternoon program continues with "Drug Discovery in the Era with Rising AI," which will be kicked off by keynote speaker Dr. Michael Snyder, Chair of Genetics at Stanford University, sharing his vision on the Future of Healthcare and Medicine. The keynote will be followed by Dr. Shirley Liu, Co-founder and CEO of GV20 Therapeutics to introduce data science-centric approaches to drug discovery, covering integrative genomics for cancer target prediction.



Lastly, we are excited to offer two dynamic panel discussions. In "Future Investment Trends in Healthcare AI", experts will deliberate on the evolving landscape of AI in healthcare. In "Precision Medicine: Empowering Healthcare for a Dynamic Future," panelists, including our distinguished speakers, will delve into how precision medicine is reshaping the delivery of healthcare.

These groundbreaking contributors have redefined the bioscience landscape, and today, they generously share their knowledge and vision with us. We eagerly anticipate their presentations, which are poised to provide fresh perspectives and chart the course for future breakthroughs.

We encourage each of you to actively participate in these discussions, exchange ideas, and establish connections with your fellow attendees. Our collective knowledge and collaborative endeavors are the driving forces behind progress in bioscience, and we have every confidence that this conference will serve as a catalyst for innovative breakthroughs.

In closing, we wish to express our deepest gratitude to the organizing committee, our sponsors, and all the dedicated individuals who have worked tirelessly to bring this event to fruition. Together, we embark on a journey of discovery, innovation, and excellence.

Once again, we extend my warmest welcome to each and every one of you. Thank you for being a part of this exceptional gathering, and let us embark on this enlightening journey together.

Shi-An Chen, PhD *Xinxin Li*

CBA Conference Co-Chairs 2023



Conference Agenda

Morning Sessions		
Opening		
8:00-8:30am	Registration, networking, and exhibition	All
8:30-8:33am	Welcome Remarks	**Shi-An Chen**, Conference Co-Chair
8:33-8:35am	State of the Association	**Xinguo Jiang**, CBA President
Morning Session 1: Dreams to Healthy Longevity		
8:35-8:40am	Opening statements / Introduction to speakers	**Shi-An Chen,** Session Chair
8:40-9:30am	**Keynote Address 1**: **Cell Rejuvenation and Disease**	**Juan Carlos Izpisua Belmonte,** PhD, Founding Scientist and Director of Science of Altos Labs
9:30-9:50am	**Finding the Weakest Link: Targeting Aging Hotspots in the Mammalian Brain**	**Oliver Hahn,** Principal Investigator, Calico Labs
9:50-10:10am	**Elucidating Cellular Senescence Heterogeneity to Develop Targeted Treatments for Chronic Diseases of Aging**	**Marco Quarta**, CEO, Rubedo Life Sciences
10:10-10:25am	Q+A	All
10:25-10:40am	**Break, Network, and Exhibition**	
Morning Session 2: Groundbreaking Chemistry in Medicine		
10:40-10:45am	Opening statements / Introduction to the keynote addressor	**Li-Fen Lee,** Session Chair
10:45-11:35am	**Keynote Address 2**: **Bioorthogonal Chemistry, the Journey from Basic Science to Clinical Translation**	**Carolyn Bertozzi,** PhD, Professor of Stanford University
11:35-11:55am	**Precision Epigenome Editing and Therapeutics**	**Stanley Lei Qi,** PhD, Associate Professor of Stanford University
11:55-12:10pm	Q+A	All
12:10-1:00pm	**Lunch, Network, and Exhibition**	



Afternoon Sessions		
Afternoon Session 1: Elevator Pitch (Presented by Winners of the CBA Entrepreneur Pitch Event)		
1:00-1:03pm	Welcome back / summary of the morning session / start of the afternoon session / lucky draw	**Xinxin Li,** Conference Co-Chair, Session Chair
1:03-1:06pm	Fueling Innovation and Entrepreneurship in Biotech: Strategic Partnership between CBA and Q Bay Center	**Dan Zhang,** VP Alliance, CBA; VP, Q Bay Center
1:06-1:25pm	**1)** Innovative diagnostics for liver diseases, **Rachel Zayas** (MBA), CEO of AGED; **2)** best-in-class treatment for inherited metabolic diseases, **Jerry Shen** (PhD), CEO of AceLink Therapeutics; **3)** brain cell organoids for CNS drug discovery, **Tao Huang** (PhD, JD), CEO of NeuCyte, **4)** siRNA-based therapy for tumor, **Brad Niles** (PhD), CEO of Priz Medicine; **5)** a novel treatment for muscular dystrophy, **David Craig** (PhD), CEO of Sacromatrix Therapeutics; **6)** new approaches for vaccine development, **Ning Li** (PhD)	
Afternoon session 2: Drug Discovery in the Era with Rising AI		
1:25-1:30pm	Opening statements / Introduction to the speakers	**Xinguo Jiang, Patrick Yang,** Session Chairs
1:30-2:20pm	**Keynote Address 3: The Future of Healthcare and Medicine**	**Michael Snyder,** PhD, Professor of Stanford University
2:20-2:50pm	**Integrated Genomics and Computation for Cancer Target and Drug Discovery**	**X. Shirley Liu**, PhD, CEO, GV20 Therapeutics
2:50-3:05pm	Q+A	All
Panel Discussion 1: Future Investment Trends in Healthcare AI		
3:25-3:30pm	Opening statements / Introduction to Panelists	**Ella Li (**PhD), Founder & CEO, H7 BioCapital, Moderator
3:30-4:15pm	Panel discussion	**Darwin ling** (MBA), Founder, Good AI Capital; **Gary Goldman** (MD, DDs, MBA), Founding Partner Global Health Impact Network and Funds; Can **Cui** (PhD, JD), Partner, Goodwin Procter LLP; **Genevieve LeMarchal** (MBA), Managing Partner, Suncoast Ventures



Panel Discussion 2: Precision Medicine: Empowering Healthcare for a Dynamic Future		
4:15-4:20pm	Opening statements / Introduction to Panelists	**Michael Zhao** (PhD), co-founder, Q-Bay (Boston), Moderator
4:20-5:05pm	Panel discussion	**Joseph Wu** (MD, PhD), Professor of Stanford University; **Dean Felsher** (MD, PhD), Professor of Stanford University; **JVu Truong** (PhD), CEO of Aridis Pharmaceuticals; **Paul Bollyky** (MD, PhD), Associate Professor of Stanford University
5:05-5:10pm	Closing remarks / lucky draw	**Xinxin Li,** Conference Co-Chair
5:10-7:00pm	**Reception, Networking**	



Morning Session I: Dreams to Healthy Longevity

Session Chair: Shi-An Chen, Ph.D. *Scientist at Altos Labs*

Shi-An is a scientist at Altos Labs, applying genomic technologies to program cellular health and reverse disease. Prior to Altos Labs, Dr. Chen was a NIEHS Kirschstein NRSA for Individual Predoctoral Fellow and Bio-X Stanford Interdisciplinary Graduate Fellow. Dr. Chen received his doctoral degree in Biology from Stanford University, where his research focused on scalable precision genome-editing technologies in fungal and mammalian systems. He has authored multiple publications in scientific journals, including Cell, Cell Genomics, Cell Research, and The CRISPR Journal, covering topics ranging from precision genome editing to epigenome regulation. Beyond research, Dr. Chen served as president of the Asian American Graduate Student Association at Stanford University, contributing to the local Asian community at Stanford. Dr. Chen was the 2021 CBA conference Co-Chair and has been volunteering for CBA since 2018.



Keynote Address I Speaker

Juan Carlos Izpisua Belmonte, Ph.D. *Founding Scientist and Director, San Diego Institute of Science of Altos Labs*

During life's early stages, cells display high levels of plasticity, regeneration, and resilience against stress, dysfunction, and injury, which are key features of human health. Dr. Juan Carlos Izpisua Belmonte, previously the Roger Guillemin Chair and Professor at the Salk Institute, has contributed towards understanding the molecular basis underlying embryogenesis and early postnatal life, as well as gaining insights into how to program and rejuvenate adult and diseased cells. He is developing technologies to program cells to states similar to those observed in the early, healthy stages of life, with the objective of developing universal health therapeutics to overcome human disease and aging.

Title: Cell Rejuvenation and Disease

Abstract: *Aging is characterized by the functional decline of tissues and organs and the increased risk of aging-associated disorders. Different rejuvenating interventions have been proposed to delay aging and the onset of age-associated decline and disease to extend health span and lifespan. These interventions include metabolic manipulation, heterochronic parabiosis, pharmaceutical administration, and senescent cell ablation. As disease and aging are associated with altered epigenetic mechanisms of gene regulation, such as DNA methylation, histone modification and chromatin remodeling, and non-coding RNAs, the manipulation of these mechanisms might be central to the effectiveness of treating disease as well as age-delaying interventions. I will discuss some of the epigenetic changes that occur during disease and aging and how partial reprogramming by the Yamanaka factors might be a potential avenue to restore cell health and resilience through cellular rejuvenation programming to reverse disease, injury, and the disabilities that can occur throughout life.*



Morning Session I Speaker

Oliver Hahn, Ph.D. *Principal Investigator at Calico Labs LLC*

Dr. Hahn is a Principal Investigator, focusing his research on brain aging at Calico Labs LLC. He obtained his M.Sc. degree from the University of Heidelberg in Germany, completing thesis at the Chinese Academy of Sciences in Shanghai. His doctoral training took place at the Max Planck Institute for the Biology of Ageing in Germany, under the guidance of Prof. Dame Linda Partridge. Following this, he pursued postdoctoral training at Stanford University in the Tony Wyss-Coray lab. The Wyss-Coray lab is dedicated to researching brain aging and neurodegeneration, with a specific emphasis on age-related cognitive decline and Alzheimer's disease.

Title: ***Finding the Weakest Link: Targeting Aging Hotspots in the Mammalian Brain***

Abstract: *Aging is a key driver of cognitive decline and the predominant risk factor for several neurodegenerative diseases, yet the molecular changes underlying brain aging remain poorly understood. Recent behavioral studies as well as structural and functional MRI data suggest that aging does not impact the brain in a uniform manner but may manifest in specific "hotspots", which are vulnerable to the aging process. Yet so far, quantitative analyses of the molecular dynamics in the aging brain have been limited. To address this, we develop and apply platforms for scalable extensive spatiotemporal RNA-seq of the mammalian brain.*

Applied to the mouse brain, our platforms generated data encompassing over 1,500 biopsies sampled from 15 regions across 7 time points and 2 rejuvenation interventions. Our analysis identified a brain-wide gene signature of aging in glial cells, which exhibited spatially defined changes in magnitude. By integrating spatial and single-nucleus transcriptomics, we found that glial aging was particularly accelerated in white matter compared with cortical regions, whereas specialized neuronal populations showed region-specific expression changes. Rejuvenation interventions, including young plasma injection and dietary restriction, exhibited distinct effects on gene expression in specific brain regions. Furthermore, we discovered differential gene expression patterns associated with three human neurodegenerative diseases, highlighting the importance of regional aging as a potential modulator of disease.

Our work identified molecular foci of brain aging and rejuvenation, providing a foundation to target age-related cognitive decline.

Morning Session I Speaker

Marco Quarta, Ph.D. *Co-Founder & CEO at Rubedo Life Sciences*

Marco co-founded and leads as CEO of Rubedo Life Sciences driving its mission to develop treatments for chronic age-related diseases and extend a healthy lifespan by selectively targeting pathological cells involved in the biological aging process. As a scientist, he earned a master's degree in biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then led at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine, co-directing the Center of Tissue Repair, Restoration, and Regeneration. He is backed by over 20 years of research with a track record of scientific publications in top-tier journals. Marco is an inventor and entrepreneur, he co-founded and led the international biotech umbrella organization Young European Biotech Network (YEBN), and later joined the European Federation of Biotechnology (EFB) executive board. Quarta founded and led the biotech company "WetWare Concepts" in Europe. In California, with his Stanford colleague Prof. Vittorio Sebastiano he also co-founded "Turn Biotechnologies" based on their work on epigenetic reprogramming of cellular aging, where he served as CSO, and he is a Board Director. Quarta sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) – Calpoly program in regenerative medicine. He is on the advisory and research board at the Center for Healthcare Innovation (CHI). He is a member of the Paul F. Glenn Center for the Biology of Aging Studies at Stanford University. Quarta keeps fostering and championing high standards of compliance, ethics, and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.

Title: Elucidating Cellular Senescence Heterogeneity to Develop Targeted Treatments for Chronic Diseases of Aging

Abstract: *Cellular senescence is a pleiotropic mechanism, functioning as a double-edged sword in physiological and in pathological functions. The proper identification of pathological senescent or senescent-like cells is key to target therapeutic drivers of diseases. However, the canonical markers of cellular senescence are insufficient to properly identify key cell types in human disease tissues. Senescent cells are heterogeneous populations that represent a small fraction of the tissue. Nevertheless, they play an important role in driving a maladaptive response in the tissue microenvironment, establishing a crosstalk with immune cells through a secretome and paracrine signaling that underlie inflammatory chronic states. This chronic inflammation can degenerate in fibrosis, loss of regenerative functions, and increased cancer malignancy. We applied single-cell multi-Omics and machine learning to identify and classify key aberrant cells with senescent properties that are characteristic of human diseased tissues. This strategy informed our drug discovery process aimed to develop a portfolio of first-in-class next-generation selective senolytics for treatments of chronic diseases of aging.*



Morning Session II: Groundbreaking Chemistry in Medicine

Session Chair: Li-Fen Lee, Ph.D. *Founder and CEO of Apeximmune Therapeutics*

Li-Fen Lee, Ph.D. is Founder, and Chief Executive Officer of Apeximmune Therapeutics. Dr. Lee is deeply versed in the fields of immunology and immuno-oncology (IO) and is a leader with over 20 years of drug development experience and expertise in multiple therapeutic areas in the biotech and pharmaceutical industry. Dr. Lee held leadership positions at Abbvie and NGM where she led the IO group and established the core IO infrastructure and helped build the IO pipeline. Dr. Lee started her career at Pfizer where she led a drug discovery group and made significant contributions to the development of therapeutic antibodies against IL-7R and various costimulatory molecules such as 4-1BB aimed at treating autoimmune diseases and cancer. Her work, which included several IND filings, patents, and numerous high-impact publications, was recognized with the prestigious Pfizer Achievement Award. Prior to joining the industry, Dr. Lee held a faculty position at the Stanford University School of Medicine. She received her Ph.D. in Cancer Immunology at the University of North Carolina, Chapel Hill where she was a recipient of the Lineberger Graduate Fellow Award and completed postdoctoral training at Stanford University.



Keynote Address II Speaker

Carolyn Bertozzi, Ph.D. *2022 Nobel Laureate in Chemistry, Director, ChEM-H & Professor at Stanford University*

Dr. Bertozzi is the Baker Family Director of Sarafan ChEM-H and the Anne T. and Robert M. Bass Professor of Humanities and Sciences in the Department of Chemistry at Stanford University. She is also an Investigator at the Howard Hughes Medical Institute. Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation, and infection, and exploiting this information for the development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology. She is an elected member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Most recently she was awarded the Nobel Prize in Chemistry, Wolf Prize in Chemistry, Dr. H.P. Heineken Prize for Biochemistry and Biophysics, and Welch Prize in Chemistry. She also was awarded the Lemelson-MIT Prize, a MacArthur Foundation Fellowship, and the Chemistry for the Future Solvay Prize, among many others.

Title: Bioorthogonal Chemistry, the Journey from Basic Science to Clinical Translation



Morning Session II Speaker

Lei Stanley Qi, Ph.D. *Associate Professor at Stanford University,*



Dr. Lei Stanley Qi is an Associate Professor of Bioengineering and Sarafan ChEM-H at Stanford University, known for his groundbreaking work in CRISPR technology. He has invented the nuclease-dead dCas and developed a range of CRISPR tools for genome editing and epigenome engineering, such as CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), and live cell DNA imaging. His research has led to discoveries in the function of the 3D genome and noncoding genetic elements in cancer and various genetic diseases. Dr. Qi received his B.S. in Physics and Math from Tsinghua University and his Ph.D. in Bioengineering from the University of California, Berkeley, where he worked with Prof. Adam Arkin and Dr. Jennifer Doudna. He was a UCSF Systems Biology Fellow at the University of California, San Francisco before joining Stanford University. Dr. Qi has won many awards, including the NIH Director's Early Independence Award, the Pew Biomedical Scholar, the Alfred P. Sloan Fellow, the NSF CAREER Award, the Blavatnik Life Science Awards, and the Chan Zuckerberg Biohub Investigator.

Title: Precision Epigenome Editing and Therapeutics

Abstract: *Precise manipulation of the genome is key to advancing the gene and cell therapy of diseases. We investigate technologies that allow precision epigenome editing without altering the human DNA codes. By developing nuclease-dead dCas systems, repurposed from bacterial Cas nucleases, we demonstrate their use for highly efficient epigenome modifications in mammalian cells. Via innovative work in Epic Bio (https://epic-bio.com), we develop a class of highly compact epigenetic editors that can be packaged onto single AAVs. We apply the precision epigenome editing tools to treat genetic diseases beyond the reach of traditional gene editing, including the second largest muscular dystrophy Facioscapulohumeral muscular dystrophy. Novel epigenome engineering holds great promise to transform future gene therapies that are safer and more potent than gene editing.*



Afternoon Session I: Elevator Pitches

Session Chair: Xinxin Li, MSPH. *VP of strategic partnerships at MyBioGate*

Xinxin is currently VP of strategic partnerships at MyBioGate where she leads deal sourcing for company investment. Xinxin devotes herself to helping scientists and entrepreneurs in advancing their venture to commercialize innovative technologies. Prior to 2020, Xinxin has organized 10+ international conferences in the U.S. and Europe including the US China Investment and Innovation Summit and the China Focus Partnering Conferences. Xinxin obtained her B.S in Chemistry from Peking University and MSPH from University of North Carolina Chapel Hill. In her free time, Xinxin enjoys sports climbing, and traveling.

Session Chair: Dan Zhang. *Vice President at Q Bay Center*

Dan is a dynamic business leader and Vice President at Q Bay Center, a Silicon Valley-based platform that connects innovation and entrepreneurship. With a background in journalism, Dan has extensive experience in media and communication, which she brings to her work in entrepreneurial eco-system building, event organization, and business development.

Prior to her current role at Q Bay, Dan held several senior positions in the tech industry, including Director of Marketing & BD at Hanhai Investments and Director of Sales/BD at Vobile (03738.HK). Dan is also a committed community leader and currently serves as the Executive Director of HYSTA (HUA YUAN SCIENCE AND TECHNOLOGY ASSOCIATION), a leading non-profit organization that empowers Chinese American entrepreneurs and leaders.



Afternoon Session I Elevator Pitch Speaker

Rachel Zayas, MSc. *Founder/CEO of AGED*

Personal Introduction: *Rachel Zayas, AGED Founder/CEO, has a Master of Science in Biotechnology and Business, and has previously launched a molecular diagnostic venture. She has worked at MIT in cancer research developing gene silencing therapeutics. Zayas has been funded by the National Science and was an adjunct instructor at George Washington University teaching business classes to technology ventures. Zayas was previously a fellow for Halcyon and Healthworx (the investment arm of BlueCross BlueShield) which selects less than 2% of applicants. Zayas has presented work at the annual Liver Disease Conference and published work in Hepatology. She has written two sci-fi fiction novels.*

Company Introduction: *AGED Diagnostics is a pre-clinical diagnostics venture developing blood tests for fatty liver disease and liver fibrosis. While liver disease affects 1 in 3 Americans, and health insurers spend $108 billion annually on management, there are no effective noninvasive tools. AGED is developing the first accurate blood test.*

Our team has completed several pilot studies to validate our core technology and identified a set of biomarkers that have between 90-99% accuracy differentiating the benign from advanced forms of liver disease from patient blood. We have multiple patents pending, have partnered with the Henry Jackson Foundation (a subsidiary of the US military), and are about to launch a 500-patient study.

AGED
DIAGNOSTICS



Afternoon Session I Elevator Pitch Speaker

Jerry Shen, Ph.D. *Co-founder and CEO of AceLink Therapeutics*

Personal Introduction: *Jerry Shen is an accomplished drug development pioneer and a multiple entrepreneur in the biopharmaceutical industry. He co-founded AceLink Therapeutics in 2018 and has served as CEO. He has raised two rounds of financing totaling ~ $30 mm and has led the Company's lead drug AL01211 to phase 2 clinical trials.*

Jerry's career in the biopharmaceutical industry started in 1998 when he joined Onyx Pharmaceuticals where he grew from a bench scientist to a drug development leader. In 2004 he co-founded Applied Biomics and led R&D activities until its acquisition in 2006. In 2007 he co-founded LEAD Therapeutics and led its drug discovery biology until its acquisition by BioMarin in 2010. In BioMarin, he led small molecule drug discovery and development. He was deeply involved in and led the successful development of three marketed drugs: Nexavar, Oncorine, and Talzenna.

B. Sc. (biology) from Fudan University; Ph.D. (mol cell biology) from State University of New York at Buffalo; postdoctoral training with Dr. Tom Shenk at Princeton University.

Company Introduction: *AceLink Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of oral therapies to address significant unmet medical needs in inherited disorders of glycosphingolipid metabolism. Founded in 2018, AceLink is headquartered in the San Francisco Bay area and has operations in the US and China.*

The leading drug candidate AL01211 is the best-in-class GCS inhibitor that offers once-a-day oral therapy for Fabry disease and type 1 Gaucher disease. In the phase 1 clinical trial, AL1211 was shown to be safe, and well-tolerated, with excellent PK/PD profiles in humans. AL1211 has started a phase 2 clinical trial in patients with Fabry disease and we also plan to start a phase 2 trial for type 1 Gaucher disease in 2023.

AceLink has finished two rounds of VC fundraising totaling close to $30 mm (Series Seed and Series A). Currently, the Company is raising Series B of $30 mm to support the clinical development of AL01211 and other drug products.

AceL
Where Science and Medicine Meet



Afternoon Session I Elevator Pitch Speaker

Tao Huang, Ph.D. *President and CEO of NeuCyte*



Personal Introduction: *Tao Huang PhD, JD, is the President and CEO of NeuCyte, an innovative biotechnology company focused on CNS drug discovery. Prior to co-founding NeuCyte, Tao has been a venture partner of a healthcare venture capital fund and a patent attorney in several prominent Silicon Valley law firms. Tao obtained his Ph.D. in Biochemistry from Peking Union Medical College and J.D. from the University of Michigan Law School. He received his postdoctoral training from the University of Colorado School of Medicine and Princeton University.*

Company Introduction: *NeuCyte develops translatable cell-based assays for modeling CNS-related disorders using patient-derived and genetically engineered neural cell types to discover novel therapeutics. Based on SynFire® technology, its proprietary human neural in vitro platforms assess cell autonomous, non-cell autonomous, and complex electrophysiological and morphological readouts suited for target identification and validation, as well as drug efficacy testing. It is actively pursuing drug discovery programs on Alzheimer's disease, ALS/FTD, Autism, and Epilepsy*

NeuCyte
Translatable Neuroscience



Afternoon Session I Elevator Pitch Speaker

Brad Niles, Ph.D. *CEO of ARIZ Precision Medicine*

Personal Introduction: *Brad Niles, Ph.D. serves as the CEO for ARIZ Precision Medicine. He received his Ph.D. from UC Davis, with a Designated Emphasis in Biotechnology and advanced training in Business Development. He has 15 years of experience in cancer research and has published more than a dozen scientific papers and was an invited speaker to numerous scientific conferences. In addition, he has managed product development projects for two different biotech startups and is an inventor of numerous RNA-therapeutic patent applications. At ARIZ he has previously served as COO and VP of Research and Development for over 4 years.*

Company Introduction: *ARIZ Precision Medicine is focused on the epigenetic changes that occur in the cancerization of a cell to develop targeted therapeutics based on the genetic differences between cancer cells and healthy cells. With an innovative approach that utilizes these differences in these cells, we are developing potentially curative drugs that specifically kill cancer cells while sparing healthy cells.*

ARIZ PRECISION MEDICINE



Afternoon Session I Elevator Pitch Speaker

David Craig, MBA. *CEO of Sarcomatrix Therapeutics*

Personal Introduction: *David Craig is a highly experienced pharmaceutical executive with a distinguished career spanning over 30 years in the industry. He is currently the CEO of Sarcomatrix Therapeutics, a pre-clinical biotechnology company focused on developing innovative treatments for muscle-wasting diseases, starting with muscular dystrophy.*

He has held several senior leadership positions in various pharmaceutical companies including Amgen, Gilead, and Alexion. He has extensive experience in drug development and commercialization and has led successful global product launches for multiple blockbuster drugs.

David is an advisor and consultant to several pharmaceutical companies, where he provides strategic guidance on clinical development and commercialization. His passion for advancing healthcare through innovative solutions and his commitment to improving patient outcomes make him a respected leader in the field.

Company Introduction: *Sarcomatrix is a preclinical stage biopharma developing novel therapeutics and enabling technologies across multiple indications, starting with muscle wasting diseases and muscular dystrophies.*

Muscular dystrophy gene therapies are still in the early stages of development, and their effectiveness in different muscle types and cells is still being studied. Our therapies should be active in all muscle types (skeletal, smooth, and cardiac), will be affordable, and be easy to administer.

Our protein replacement program features recombinant human Laminin-111, the embryonic form of laminin, demonstrating activity in many muscular dystrophies in addition to LAMA2-RD congenital muscular dystrophy.

SARCOMATRIX



Afternoon Session I Elevator Pitch Speaker

Ning Li, Ph.D. *CEO of Gasilus Pharma*

Personal Introduction: *Dr. Li is a seasoned biotech scientist with over 20 years of experience at leading biotech companies, including Tularik, Amgen, Exelixis, and Gilead. His research has focused on cancer target validation, assay development, HTS, immunology, and vaccine development.*

He is currently the CEO of Gasilus Pharma, where he is leading the development of innovative vaccine delivery systems. Dr. Li is a passionate advocate for the development of improved vaccines. He believes that chimeric gas vesicle protein nanoparticles have the potential to revolutionize vaccine development.

Company Introduction: *Gasilus Pharmaceuticals is a startup biotech company developing gas vesicle (GV) vaccines for infectious diseases and cancer therapies. GVs are proteinaceous and gas-filled nanoparticles naturally found in many bacteria. Gasilus has successfully developed the proprietary chimeric gas vesicle (CGV) nanoparticles technology, in which foreign peptides up to 62-AA can be fused genetically with gas vesicles.*

Preliminary animal experiments have shown that CGV-based vaccines can be effectively delivered via intranasal administration and elicit both mucosal and humoral immune responses. Mucosal immunity is important for preventing respiratory infections such as COVID-19.

In addition to its potential for COVID-19 vaccines, CGV technology could also be used to develop vaccines for other infectious diseases, such as influenza and HIV. It could also be used to develop cancer vaccines.

Gasilus

Afternoon Session II: Drug Discovery in the Era with Rising AI

Session Co-Chair: Patrick Yang, Ph.D. *Director at Latigo*

Dr. Yang is currently the Director at Latigo. He has been working mainly in the Bay Area for many years in various pharmaceutical companies in the field of CMC including analytical development and quality control. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA.

Patrick has been serving on the CBA board for several terms since 2003. His roles include directors of membership, activity, and alliance. He successfully organized CBA education seminars and has been working as a committee member for the Ho Family Scholarship. He was the president of CBA in 2017 and is now a CBA advisor.

Besides CBA board member's duty, Patrick also participated in many other activities in the Bay Area. He helped organize a big literature seminar for Sichuan earthquake fundraising, led local student math team and science bowl teams, took judge and judge leader roles in the Silicon Valley science fair, and served as CABS journal editor for "Trends in Bio/Pharmaceutical Industry" for seven years. He is also an active writer with many readers.

Session Co-Chair: Xinguo Jiang, MD, Ph.D. *Director/Sr. Principal Scientist at Apeximmune Therapeutics*





Xinguo is Associate Director/Sr. Principal Scientist at Apeximmune Therapeutics, where he leads efforts in elucidating target biology mechanisms and translational medicine. Dr. Jiang is also a PI at VA Palo Alto, studying hypoxic signaling and leukotriene biology in various human diseases. He received his Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign, and a degree in Medicine from Zhejiang University in China. Dr. Jiang completed his post-doc training at Stanford University. He has authored more than 45 peer-reviewed articles spanning areas such as tumor immunity, pulmonary hypertension, COPD, lymphedema, and transplant rejection; his significant contributions have been featured in journals such as Circulation, JCI, AJRCCM, and Annual Reviews.

Keynote Address III Speaker

Michael Snyder, Ph.D. *Chair of Genetics Department, Stanford University School of Medicine*



As a pioneer of Precision Medicine, Dr Michael Snyder has invented many technologies enabling the 21st century of healthcare including systems biology, RNA sequencing, and protein chip. Dr Snyder has initiated the Big Data approach to healthcare through his work using omics to detect early-stage diseases, including wearables to detect infectious diseases like COVID-19, and at-home microsampling to measure hundreds of molecules from a single drop of blood. He is the first researcher to gather petabytes of data on individuals, which is 1 million - 1 trillion times more data than the average clinician collects. He has published over 800 papers and is one of the most cited scientists. In terms of commercial success, Mike has co-founded 17 companies (including 2 unicorns) with a combined enterprise value of over $6 billion.

Title: The Future of Healthcare and Medicine

Abstract: *Why go to a doctor when you are sick? Why go to a doctor at all? In the future medicine will transform from sick care to health care—keeping people healthy and catching disease early rather than waiting until they are sick. Much of healthcare will involve remote monitoring to track health. Wearable devices-- presently smartwatches and rings and in the future, implantables—will track your physiology such as heart rate, heart rate variability, and temperature. Tiny pricks of blood will measure key analytes (health markers) instantly and overnight mail of similar tiny samples will ready hundreds, if not thousands, of your biomarkers. Together with the data above, monitors of your face and communication will track*



your stress levels and mental health. We will enter a world where health tracking will be automatic, much like the sensor on your car tracks your automotive's health. Our lab is trying to make a lot of this happen.



Afternoon Session II Speaker

X. Shirley Liu, Ph.D. *Co-founder & Chief Executive Officer at GV20 Therapeutics*



Dr. Liu received a Ph.D. in Biomedical Informatics and a Ph.D. minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, Dr. Liu has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. Her research work focused on algorithm development and data integration modeling for translational cancer research. She has published over 250 peer-reviewed papers and has an H-index of 114. Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), and the American Institute for Medical and Biological Engineering (AIMBE), and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), the Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), the ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 25 PhD and postdoc trainees to independent academic careers.

Title: Integrated Genomics and Computation for Cancer Target and Drug Discovery

Abstract: *Despite the exciting clinical benefits of immune checkpoint inhibitors, only a minority of cancer patients respond to treatment. Addressing resistance to immune checkpoint inhibitors is an urgent unmet need and requires new approaches for target identification and drug discovery.*

GV20 Therapeutics adopts an interdisciplinary approach integrating functional genomics, big data AI, and cancer immunology for cancer target identification and drug discovery. Our platform computationally extracts antibodies from large cohorts of patient tumor RNA-seq profiles and uses AI to pair targets and corresponding antibodies in silico, de novo with speed and scale. We then leverage in-house and public functional genomics and proteomics data to de-risk the AI-identified targets from patient tumors and provide insights on target function before we conduct systematic in vitro and in vivo validation experiments.

We used this approach to discover our lead program, GV20-0251, which is a first-in-class monoclonal antibody against a novel immune checkpoint IGSF8. In multiple syngeneic tumor models, anti-IGSF8 antibody has single-agent efficacy and is synergistic with anti-PD1 in controlling tumor growth, and the safety of GV20-0251 is currently being tested in the clinic. Our efforts represent the beginning of rationally combining genomics and AI to unlock the hidden information from patient tumors to develop cancer immunotherapeutics.



Panel Discussion I - Future Investment Trends in Healthcare AI

Session Chair: Ella Li, Ph.D. *Founder & CEO at H7 BioCapital*

Dr. Ella Li is the founder and CEO of H7 BioCapital, a venture platform that supports the transformational growth of healthcare companies. She is also a venture partner of Network VC, focusing on seed to series A investment in the healthcare sector. She has also founded M7 Accelerator. Prior to that, she was the CEO of Hanhai BioLabs, leading the team in life science investment. She was also the former CEO of ZGC Capital and the partner of its U.S. funds. She has established and managed several VC and fund of funds, including one with portfolio funds such as KPCB, Menlo, Andreessen Horowitz, Accel, Foundation Capital, and IVP.

Dr. Li has over 10 years of experience in biotech research and has rich experiences in therapeutic investment opportunities from discovery and clinical proof-of-concept to commercialization. Dr. Ella Li earned her B.S. and M.S. degrees from Peking University and her Ph.D. from the University of Texas Health Science Centers. She completed her postdoctoral fellowship at Harvard Medical School, where she led five independent projects exploring novel therapeutic targets for metabolic disease. Dr. Li has extensive publications in prestigious journals with IMF over 10 including Nature Communication, Cell Metabolism, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences (PNAS), Molecular Cell, and Diabetes.

Panel Discussion I Panelist

Darwin Ling, MBA. *Founder and General Partner at Good AI Capital*

Darwin Ling is the founding general partner of Good AI Capital, a mission-driven venture fund focusing on early-stage AI companies in Healthcare, Enterprise, and Automation. Prior to that, he was an entrepreneur with multiple exits, a technologist as well as an angel investor in successful unicorns such as SoFi.

Most recently, Darwin served as the CTO and co-founder of SmarterMe, which aims to improve sales productivity by bringing AI / Intelligence to the flow of work. Counting enterprise customers such as Danaher (Fortune 500 medical device), Home Depot, and GE, SmarterMe was recently acquired.

As a Distinguished Alumni of Purdue University, Darwin was featured as one of Purdue's Tech Titans and is serving on the leadership council for the School of Science. As an expert in AI/Machine Learning and Precision Medicine, Darwin is a guest lecturer for the Chicago Booth of Business.

Darwin received his MBA (Honors) from the University of Chicago Booth School of Business. He also holds a BS (Phi Beta Kappa) with distinction in Computer Science and Mathematics and an MS in Computer Science, both from Purdue University.



Panel Discussion I Panelist

Gary Goldman, DDS, MD, MBA. *Founding Partner at Global Health Impact Network and Funds*

Gary Goldman DDS MD MBA has a 35-year career as a clinician Anesthesiologist with fellowships in Obstetric and Neuro Anesthesiology, practice administration and as a medical director, medical executive board member, enterprise physician Informaticist, ACCMA medical association council member, serial entrepreneur and is currently the founder of the Global Health Impact Network and Funds (GHIF/GHIN). GHIF/N was founded in 2019 with a vision to give physicians and other healthcare professionals a cloud-based collaboration platform to safely and securely collaborate, communicate, educate, and actively participate, as strategic investors, advisors, and consultants in the evolving Digital Health Revolution

Global Health Impact Network (GHIN) is an organization that is founded, designed, and driven by clinicians who want to take back control of healthcare delivery. Our mission is to improve access, efficiency, and safety and to decrease the cost of healthcare by leveraging digital health innovation and technology through the active guidance of clinician entrepreneurs, advisors, and investors across the entire ecosystem of the evolving digital health revolution. We have created a global ecosystem that supports healthcare innovation from idea generation through commercialization.

Global Health Impact Fund (GHIF), is a clinician-founded and managed Digital Health focused Venture Fund that promotes active participation by health professionals in the evolving digital health revolution. GHIF leverages the subject matter expertise of its global network of clinicians, healthcare professionals, and domain experts with its proprietary HandzIn platform promoting collaboration, communication, education, active participation, and democratization of investment opportunities, creating an ecosystem focused on healthcare innovation and acceleration.



Panel Discussion I Panelist

Cui Can, Ph.D., J.D. *Partner at Goodwin Procter LLP*

Dr. Can Cui is a partner in the Life Sciences practice group of Goodwin Procter LLP and a co-leader of the firm's Life Sciences practice in Asia. His practice focuses on technology transactions and investment in the life sciences industry, especially those transactions related to China, including cross-border technology licensing and acquisition, collaboration and strategic partnership, joint venture (JV), and other forms of investment.

Dr. Cui has extensive experience representing both licensors and licensees in U.S.-China life sciences licensing transactions. In private equity and venture capital transactions, he regularly represents institutional and individual investors, established life sciences companies, and startups in intellectual property (IP) due diligence and the negotiation and drafting of related investment documentation. He also advises clients on IP aspects of mergers and acquisitions.

Dr. Cui has deep knowledge of China's increasingly complex regulatory landscape, including not only the IP laws but also regulations governing cross-border transactions, such as technology import and export regulations and regulations of human genetic resources. He also has rich experiences in corporate matters, patent prosecution, and IP dispute resolution, which, together with his scientific background, make him a go-to person for advice in various legal matters life sciences companies may have.

Dr. Cui has been selected for inclusion in The Legal 500 U.S. 2022, and is recognized by the Berkeley Center for Law & Technology as one of the "leading practitioners in biotech and life sciences."

Dr. Cui received his B.Sc. in Biotechnology from Peking University, his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, and his J.D., magna cum laude, from New York University School of Law.



Panel Discussion I Panelist

Genevieve LeMarchal, MBA. *Managing Partner at Suncoast Ventures*

Genevieve LeMarchal is the Managing Partner of Suncoast Ventures, an early-stage venture capital fund specializing in healthcare impact and equity funding opportunities in medical AI, digital health, health tech, medtech, and select therapeutics. She launched and ran Expert Dojo's healthcare program and ran 3 full cohorts of health tech and medtech companies, becoming one of the most prolific early-stage vc investors in Southern California (Crunchbase, 2022) and winner of the 2022 Biocom Lifescience Catalyst Award. She loves to innovate financial models and find better ways to structure and fund companies and deals. She previously served as a Partner at a science-focused advisory and fund in formation, was a General Partner at Oregon-based FoundersPad VC Fund II and she is the co-founder of the XXcelerate Fund. She is the host of the AdVentureous Podcast. Genevieve writes and delivers talks, keynotes, and training programs to groups all over the world about venture capital and entrepreneurship, impact and equity investing, and more.

She is a Pacific Northwest native and now resides in the San Francisco Bay Area.

Panel Discussion II - Precision medicine: empowering healthcare for a dynamic future

Session Chair: Michael Zhao, Ph.D. *Q Bay (Boston) Co-founder*

Michael Zhao started Longwood Biology Inc with friends after graduating from Harvard Medical School in 2014, aiming to develop effective and low-toxic anti-neurodegenerative drugs from small molecules, and translating bench work to bedside therapies for Alzheimer's disease. He founded LB Ventures in 2016 for early-stage startups in the biotech industry. LB Ventures invests globally across the spectrum of healthcare companies including pharmaceuticals, medical devices, and medical services, focusing on developing and expanding early-stage life science and technology companies with strong potential to achieve global success in their markets. In 2018, he joined K50 Ventures as a partner for the development of the biotech sector with the faith that everyone deserves access to affordable preventative care, specialty care, and mental health support. In 2020, he joined Q Bay (Boston) Center focusing on the platform to support innovation and connect entrepreneurs. Q Bay is committed to accelerating start-up development by leveraging technology resources and finance accessibility while building a diverse community.

Panel Discussion II Panelist

Dean Felsher, M.D., Ph.D, *Professor of Medicine at Stanford University*

Dr. Felsher is a distinguished medical professional, holding positions as Professor in Medicine - Oncology and Pathology. He is actively involved in esteemed institutions such as Bio-X, Maternal & Child Health Research Institute (MCHRI), and Stanford Cancer Institute. With administrative roles, including Director of Translational Research and Applied Medicine and Co-Director of the Cancer Nanotechnology Program at Stanford University School of Medicine, Dr. Felsher has earned recognition through memberships in the Association of American Physicians and the American Society of Clinical Investigation. His impressive academic journey encompasses a BA from the University of Chicago and an MD and PhD in Medicine/Molecular Biology from UCLA, with his research contributing significantly to cancer treatment advancements.

Panel Discussion II Panelist

Joseph Wu, M.D., Ph.D. *Professor at Stanford University*

Dr. Wu is a highly accomplished board-certified cardiologist, serving as the director of the Stanford Cardiovascular Institute and holding the prestigious Simon H. Stertzer, MD, Professorship of Medicine and Radiology at Stanford University School of Medicine. Notably, he has been appointed President of the American Heart Association for the fiscal year 2023-2024. Dr. Wu's clinical interests focus on adult congenital heart disease and cardiovascular imaging, aiming to optimize heart health and enhance patients' quality of life. He is a prolific researcher with over 550 published manuscripts and ranks among the world's most highly cited scholars in cardiovascular medicine, stem cells, genomics, and precision medicine. His research goals include advancing understanding of cardiovascular diseases, accelerating drug development, and promoting personalized precision medicine at Stanford Medicine. Dr. Wu's exceptional contributions have earned him numerous honors and prestigious memberships, and he continues to educate and inspire future heart specialists.

Panel Discussion II Panelist

Vu Truong, Ph.D. *CEO at Aridis Pharmaceuticals*

Dr. Truong is currently CEO and CSO of Aridis Pharmaceuticals. He has over 25 years of experience in biopharmaceutical drug development, focusing on the discovery and development of human monoclonal antibodies and vaccines. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody-based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products, APEXTM human mAb discovery and production platform technology, and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

Afternoon Session IV Panelist

Paul Bollyky, MD, Ph.D. *Associate Professor of Medicine at Stanford University*

Dr. Bollyky is an accomplished Immunologist and Infectious Disease specialist at Stanford Medical Center. His clinical expertise centers on infectious diseases, specifically wound infections, microbial biofilms, diabetic wounds, chronic skin and lung infections, and chronic bacterial infections. As an Associate Professor in Medicine - Infectious Diseases and Microbiology & Immunology, he contributes significantly to academic research and holds memberships in esteemed institutes such as Bio-X, Cardiovascular Institute, Maternal & Child Health Research Institute (MCHRI), and Wu Tsai Neurosciences Institute. Dr. Bollyky's outstanding contributions have earned him numerous honors, including the Fellowship in the Infectious Disease Society of America and membership in the American Society of Clinical Investigators (ASCI). He completed his medical education at Harvard University, pursued a PhD at Oxford University, and received further training through fellowships at the University of Washington Infectious Disease Program and Brigham and Women's Hospital Internal Medicine Residency.

CBA Organizing Committee

2023 Board Members

President: Xinguo Jiang, MD, Ph.D.
Vice President and 2023 Conference Co-Chair: Shi-An Chen, Ph.D.
Vice President and 2023 Conference Co-Chair: Xinxin Li
Vice President of Alliance: Dan Zhang
Operation and Membership Director: Frank Zhou, Ph.D.
Volunteer Director: Anne Tseng, Ph.D.
Volunteer Director: Audrey Hong, Ph.D.
Sponsorship Director: Charlie Ao, M.S.
Communication Director: Jessie Zhang, M.S, MBA.
Treasurer: Kai-wen Cheng, Ph.D.
Scientific Affairs Director: Wanwan Yang, Ph.D.
Webmaster: Jia Jun Chia, M.S.

Advisors

Li-Fen Lee, Advisor (2022 CBA President)
Shuming Liu, Advisor (2021 CBA President)
Dannis Chang, Advisor (2020 CBA President)
Huifang Li, Advisor (2019 CBA President)
Mark Chen, Advisor (2018 CBA President)
Patrick Yang, Advisor (2017 CBA President)
Kai Zheng, Advisor (2016 CBA President)
Shih-Chen Chang, Advisor (2015 CBA President)
Michelle Chen, Advisor (2014 CBA President)
Lin Sun-Hoffman, Advisor (2013 CBA President)
Patty Kiang, Advisor (2011 CBA President)
Sydney Chen, Advisor (2010 CBA President)
Kelley Liu, Advisor (2007 CBA President)
Shian-Jiun (SJ) Shih, Advisor (CBA Founding President)

Volunteers *JingWen Cai, Xiaopei Chen, Kristen Chen, Bee Cheng, Xingyu Jiang, Weicheng Li, Rylie Liu, Xinye Qian, Jade Su, Shengqin Su, Christina Wang, Amy Yang, Kaiqing Zhang*



CBA Key Events: CBA Seminar

Advancing Healthcare through Innovation

Date: May 14, 2023,

Venue: Q Bay Center, 160 East Tasman Drive, San Jose CA 95134

Organizers: CBA, Medicilon, Q Bay

In celebration of Mother's Day, the CBA science community gathered for an enlightening mini symposium that showcased the latest advancements in AI drug design, gene editing, and RNA drug safety evaluations. Dr. Ho Leung Ng, founder of Rise Bio, Professor Chenjian Li at Stanford University, and Dr. Renzong Xie, DABT and VP of Medicilon, as the featured speakers, shared their expertise and innovative methodologies, sparking engaging discussions and fostering a sense of scientific community among the attendees. The event served as a testament to the collaborative spirit of the scientific community to shape the future of medicine.

CBA Chinese Bioscience Association

Key events: CBA Entrepreneur Pitch

Date: August 18, 2023

Venue: Q Bay Center, 160 East Tasman Drive, San Jose CA 95134

Organizers: CBA, Mybio, Q Bay (sponsor, BICI)

Entrepreneurs in the life science sectors have faced significant challenges in 2022-2023. The fundraising difficulties faced by startups have served as a catalyst for community collaboration, uniting us in support of resilient entrepreneurs who are dedicated to developing robust scientific advancements with viable business potential. The CBA entrepreneur pitch was organized to assist local entrepreneurs in overcoming this challenging phase.



CBA Chinese Bioscience Association

Key events: CBA Picnic

Date: August 19, 2023

Venue: Q Bay Center, 160 East Tasman Drive, San Jose CA 95134

Organizers: CBA (sponsor, Medicilon)

The picnic functioned as a significant platform for reconnecting and strengthening bonds among attendees. For the long-standing CBA members, it was an opportunity to rekindle old friendships and reminisce about shared experiences. Meanwhile, the newcomers found themselves warmly welcomed into the CBA fold, where they could forge new connections and immerse themselves in the organization's vibrant community.

CBA Chinese Bioscience Association

Key events: CBA Picnic

Sponsors

Diamond Sponsor

Q BAY center | 钱塘中心

Sapphire Sponsor

SB Sino Biological

Platinum Sponsors

BIOSYSTEMS Acro

MagStone LAW

SNOW LAKE



Gold Sponsors

BioProMind

NSTC 國家科學及技術委員會
National Science and Technology Council

FirGenix

InvestHK

Formosa Laboratories, Inc.

NOVOTECH™
The Asia Pacific CRO

GBC General Biologicals Corporation

PANACEA VENTURE



Silver Sponsors

GenScript
Make Research Easy

MYCENAX
BEST PARTNER

新竹科學園區
Hsinchu Science Park Taiwan

Cellentia

GOODWIN

工業技術研究院
Industrial Technology Research Institute

Miltenyi Biotec

BIOCYTOGEN

NEW HOPE 新希望 華人癌症關懷基金會
CHINESE CANCER CARE FOUNDATION

NEW YORK LIFE

myBio 美柏医健

Medicilon
Medicilon Inc.
Integrated Drug Discovery Services

PreciGenome

CBA Chinese Bioscience Association

Media Partners:

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

H7 BIOCAPITAL

硅谷脱口秀 GGTKX.ORG

戴歌在谷

硅星人

CHINESE ENTREPRENEURS ORGANIZATION
华人创业者协会

ACE@Berkeley
Association of Chinese Entrepreneurs at Berkeley
加州大学伯克利分校 华人创业者协会

PBSS
Pharmaceutical & BioScience Society
International

华源 HYSTA

CHI HUO




Q BAY
Q Bay Center
Innovating/ Developing / Empowering / Accelerating
About
Q Bay Center, founded by Hangzhou Overseas Center Inc., is a Silicon-Valley-based platform to connect and support innovation and entrepreneurship. With a tripartite mission of "Platform + Investment + Services", Q Bay Center is designed as an innovative business model which combines real property, business exhibition, financial activity, technology cooperation, business services and startups incubation. By leveraging the synergy of technology, finance, industrial ecology and culture, the center is committed to enhancing connection and empowering development.
We provide
Workspace
Biomedical Lab
Incubation Acceleration
Funding
Exhibition
Service
Events
Mentors
Contact
info@qbay.com
https://qbay.com
160 E Tasman Dr, San Jose, CA 95134
Wechat
Newsletter




BIOSYSTEMS
Acro
Recombinant Proteins
Antibodies
Assay Kits
Custom Services
GMP Manufacturing
Partner With Us
A Cornerstone of the Global Health & Biopharma Industries
Better Design
Better Quality
Better Support
Better Response

CBA Chinese Bioscience Association


EIRGENIX
WE MAKE BIOLOGICS
EirGenix
台康生技股份有限公司
PIC/S GMP CERTIFICATIONS
• US FDA Inspected (EIR Approval Received)
• Japan PMDA Approved
• Taiwan FDA Approved
• EU EMA Inspection Pending (Expected Q3/Q4 2023)
FDA
Pmda
CDMO SERVICES
FULL ONE-STOP SERVICE PROVIDER FOR ALL YOUR BIOLOGICS
Monoclonal and Bi-specific Antibodies, Recombinant Proteins & Protein Vaccines, Antibody-Drug Conjugates (ADCs), Plasmid DNAs & Viral Vectors
GMP MANUFACTURING
Mammalian Production
• Total Capacity: 29,400 L
• 2 X 200 L, 5 X 1,000 L, 12 X 2,000 L SUBs
(3 x 15,000 SSB by 2026)
Microbial Production
• Total Capacity: 180 L (1,530 L by 2024)
• 1 X 30 L, 1 X 150 L Fermentors
(1 x 350 L, 1 x 1,000 L Fermentors by 2024)
CELL LINE DEVELOPMENT
UPSTREAM/DOWNSTREAM PROCESS DEVELOPMENT
ANALYTICAL SCIENCES & QUALITY CONTROL
PRODUCT DEVELOPMENT
BIOSIMILAR CO-DEVELOPMENT AND LICENSING OPPORTUNITIES AVAILABLE
PRODUCT
PRE-CLINICAL
PHASE I/II
PHASE III
MAA/BLA
HER2/HAAL1 PRODUCTS
EG12014/EG1014 Trastuzumab Biosimilar
SANDOZ
SIGNED LICENSE AGREEMENT WITH NOVARTIS'S SANDOZ
TSY0110/EG12043 ADC Biosimilar
FORMOSA
CO-DEVELOP WITH FORMOSA PHARMACEUTICALS, INC.
EG1206A Pertuzumab Biosimilar
EG13074 TRZ Biosimilar (SC Formulation)
EG13084 TRZ+PRZ Biosimilar (SC Formulation)
EG62054 Biosimilar
EG74032 CRM197 Carrier protein I for conjugate Vaccines


FORMOSA
LABORATORIES, INC.
Strategic CDMO partner for your success
Fulfill all your needs in API, Fermentation, Peptide, ADC, and Injectables
A/XDC
Injectable
Fermentation
FORMOSA
Peptide
HPAPI
Inspected by PMDA, FDA, EMA...
Active Pharmaceutical Ingredient
Bring your lab sample to commercial product
• Cytotoxic/High Potency Manufacturing
• Versatile Carrier-Drug Conjugation (ADC)
• Peptide Synthesis
• Fermentation Services
• Injectable Manufacturing Services
• GMP-compliant inspected by PMDA, FDA, EDQM, BGV, COFEPRIS and TFDA
• PIC/S GMP for cytotoxic/high potency filling line
• PIC/S GDP for labeling packaging and logistics
www.formosalab.com

Please contact us at sponsorship@cbasf.org for future CBA sponsorship opportunities.

CBA Chinese Bioscience Association

A Nonprofit and Volunteer Organization